<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141216">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01864083</url>
  </required_header>
  <id_info>
    <org_study_id>11-177</org_study_id>
    <nct_id>NCT01864083</nct_id>
  </id_info>
  <brief_title>FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients</brief_title>
  <official_title>FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan-Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan-Kettering Cancer Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has been designed to help us determine if FACBC PET or PEM can accurately
      evaluate how far the breast cancer has spread in the breast. Also, to help determine if
      FACBC PET or PEM can accurately measure your response to chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>assess the diagnostic accuracy</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Accuracy of standardized uptake values will be analyzed by receiver operating characteristic (ROC) curves. ROC curves will be constructed separately for FACBC PET, FACBC PEM and MR. The area under the curve will be used as a summary measure and compared using the standard nonparametric test [20]. We will also consider dichotomizing the uptake and present accuracy using sensitivity, specificity and predictive values. Dichotomized values will be compared using the McNemar test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ability of FACBC PET and PEM to determine therapeutic response to neoadjuvant chemotherapy</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients with locally advanced IDC or ILC, requiring neoadjuvant therapy prior to definitive surgery, will undergo FACBC PET and PEM both before chemotherapy and after. Following definitive breast surgery, pathologic specimens will be analyzed to determine if FACBC imaging can predict pathologic treatment response.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Local staging patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Breast MR and FACBC PET/PEM will be scheduled within one week of each other. Breast MR is a standard clinical examination and will be performed as standard.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baseline FACBC PET/PEM will be scheduled within 1 week of beginning neoadjuvant therapy. A repeat FACBC PET/PEM will be scheduled after the conclusion of neoadjuvant therapy, and before definitive surgical management.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography (PET)</intervention_name>
    <arm_group_label>Local staging patients</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)</intervention_name>
    <arm_group_label>Local staging patients</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron emission mammography (PEM) When available</intervention_name>
    <arm_group_label>Local staging patients</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MR</intervention_name>
    <arm_group_label>Local staging patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women presenting for evaluation at MSKCC with biopsy proven primary IDC or ILC

          -  No prior therapy for IDC or ILC

          -  Clinical need for local disease staging with breast MR (Group A only)

          -  Clinical need for neoadjuvant chemotherapy (Group B only)

          -  Patients must provide written informed consent

        Exclusion Criteria:

          -  Age &lt;21 years

          -  Men

          -  Pregnancy or lactation

          -  Patients who have already started treatment for the current malignancy

          -  Patients who cannot undergo PET scanning (i.e. because of weight limits)

          -  Patients who are known to have contraindication for MRI (e.g. metal implants)

          -  Patients may only participate in group #1 or group #2, but not both
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Ulaner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan-Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary Ulaner, MD, Phd</last_name>
    <phone>212-639-3776</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heiko Schoder, MD</last_name>
    <phone>212-639-2079</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Ulaner, MD,PhD</last_name>
      <phone>212-639-3776</phone>
    </contact>
    <contact_backup>
      <last_name>Heiko Schoder, MD</last_name>
      <phone>212-639-2079</phone>
    </contact_backup>
    <investigator>
      <last_name>Gary Ulaner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>May 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FACBC PET/PEM</keyword>
  <keyword>MR</keyword>
  <keyword>11-177</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
